AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03759951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT-2
Description: A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
Study NCT03759951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT-3
Description: A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
Study NCT03759951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No training will be performed during a 1-year period. Participation only in measurements.
Study NCT00972452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: short period of exercise training (5-10 days)
Study NCT01748877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXN-462
Description: Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
Study NCT01748877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
Study NCT01704768 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE/Healthy Lifestyles TEEN Program.
Description: The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
Study NCT01704768 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Teens Attention Control Program
Description: The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
Study NCT00836095 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Supreme Laryngeal mask airway
Description: Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
Study NCT00836095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal laryngeal mask airway
Description: Proseal is a multiple use, variant of the laryngeal mask airway
Study NCT02947269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg capsule
Study NCT02947269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo capsule
Study NCT01795482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Description: In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
Study NCT02830971 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Doing Different ICU techniques and skills
Study NCT03794687 — intervention group
Intervention type: PROCEDURE
Intervention: Left heart catheterization
Description: Catheterization via the distal radial artery
Study NCT03575988 — intervention group
Intervention type: OTHER
Intervention: Diabetes
Description: The patients have diabetes without diabetic retinopathy from the diabetic outpatient
Study NCT03946579 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: self questionnaires
Description: FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
Study NCT02351817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Ostomy appliance
Study NCT04589741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Toripalimab Combined With CAV/IE chemotherapy
Description: CAV/IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and scheme 2: IFO 1.5g/m2 D1-5 + vp-16 90mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks;~The patients were treated with toripalimab (240mg, 6ml) intravenously every 3 weeks;~If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (50mg/m2) or IE regimen can be used~After 6 courses of treatment, patients with disease control (CR + PR + SD) and tolerable adverse reactions were treated continuously. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment.
Study NCT04589741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Combined With CAV/IE chemotherapy
Description: CAV/IE regimen alternate chemotherapy (regimen 1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and scheme 2: IFO 1.5g/m2 D1-5 + vp-16 90mg / m2 D1-5, IV drip). Regimen 1 and 2 were performed alternately, with a cycle of 3 weeks;~The patients were treated with toripalimab (240mg, 6ml) intravenously every 3 weeks;~If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (50mg/m2) or IE regimen can be used~After 6 courses of treatment, patients with disease control (CR + PR + SD) and tolerable adverse reactions were treated continuously. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment.
Study NCT04589741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CAV/IE alternate chemotherapy
Description: CAV/IE alternate chemotherapy (regimen1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and regimen2: IFO 1.5g/m2 D1-5 + VP-16 90mg/m2 D1-5, IV drip), regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.~Patiens with disease control (CR+PR+SD) and tolerable adverse reactions were treated continuously with a maximum of 8-10 cycles. If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (≥ 60 years old: 35mg/m2, \< 60 year old: 40mg/m2) or IE regimen can be used. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment.
Study NCT04589741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAV/IE alternate chemotherapy
Description: CAV/IE alternate chemotherapy (regimen1: CTX 1.2mg/m2 D1 + ADM 50mg/m2 D1 + VCR 1.4mg/m2 D1 and regimen2: IFO 1.5g/m2 D1-5 + VP-16 90mg/m2 D1-5, IV drip), regimen 1 and 2 were performed alternately, with a cycle of 3 weeks.~Patiens with disease control (CR+PR+SD) and tolerable adverse reactions were treated continuously with a maximum of 8-10 cycles. If doxorubicin has reached the upper limit or reduced cardiac toxicity, liposome adriamycin (≥ 60 years old: 35mg/m2, \< 60 year old: 40mg/m2) or IE regimen can be used. The study was completed when the researchers considered that the patients were not suitable for continuous medication or the efficacy evaluation was disease progression (PD). No other anti-tumor treatment can be carried out during the treatment.
Study NCT02488915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmboTrap® Revascularization Device
Study NCT03146923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Low Phosphorus Diet Prescription
Description: Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides \<15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition \& Dietetic Institute (INDI) in 2010 and includes following main components:~* Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~* Restricting dairy intake (1-1.5 portions per day)~* Avoiding foods high in phosphate~* Avoiding foods with phosphate additives
Study NCT03146923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Low Phosphorus Diet Prescription
Description: Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~* Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~* Increased focus on avoiding additives~* Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~* Avoiding over-prescription of protein which carries an obligatory phosphorus load.~* Focus on high protein foods with a low phosphorus to protein ratio
Study NCT04054986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F-Var3 PET/CT
Description: Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.
Study NCT04054986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
Study NCT03823521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardioplegia Solution
Description: Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
Study NCT03820843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art therapy and standard orthophonic rehabilitation
Description: In addition to standard orthophonic rehabilitation, the patient will receive 12 sessions of art therapy
Study NCT01614886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: 1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
Study NCT01614886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENA713
Description: -3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
Study NCT01980017 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ottawa Model for Smoking Cessation
Study NCT00190749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5-20 mg, oral, capsules, daily, 12 weeks.
Study NCT00190749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
Study NCT00518492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Blood draws at 6 and 12 months following end of 6108A1-500 trial.
Study NCT04235179 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
Study NCT01845909 — intervention group
Intervention type: OTHER
Intervention: ECG and survey screening
Study NCT01025401 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: 3-D accelerometric and magnetic sensors
Description: sensors are positioned on the right wrist, the left wrist and on the head.
Study NCT03592550 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: Abdominal ultrasound imaging of the liver
Study NCT04032054 — intervention group
Intervention type: DEVICE
Intervention: mono-axial and poly-axial screws
Description: types of pedicular screws for thoracolumbar fractures fixation
Study NCT04495101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prolastin
Description: Intravenous infusion 120 mg/kg
Study NCT04495101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard medical treatment per local policies or guidelines
Study NCT04495101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard medical treatment per local policies or guidelines
Study NCT01607632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: loving-kindness meditation
Description: A 12-week duration, 90 minute per session loving-kindness meditation course
Study NCT02073747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: One hour inhaled normal saline
Study NCT02073747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: One hour inhaled ten milligrams of albuterol
Study NCT03664089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ankle weights (2.5 pounds [1.1 kg]/ankle)
Description: Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds \[1.1 kg\]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
Study NCT03664089 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
Study NCT02270515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home for Kidney Disease (PCMH-KD)
Description: A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
Study NCT04328883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral and inhaled ASA formulations
Study NCT04328883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Oral and inhaled ASA formulations
Study NCT00398554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
Study NCT00398554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25mg/m²/day, 2 hours i.v.infusion on day 21
Study NCT00398554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
Study NCT00398554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
Study NCT00398554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Description: 6 mg/m² i.v. bolus on day 1 and day 21
Study NCT00398554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
Study NCT03733015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
Study NCT03216512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Noise Cancelling Headphones
Description: During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
Study NCT01748292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg ranibizumab
Description: Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
Study NCT01748292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Description: Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
Study NCT02191111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-focused facilitation
Description: An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
Study NCT02614001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA
Description: Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
Study NCT02614001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: post-stroke rehabilitation program
Study NCT02614001 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post-stroke rehabilitation program
Study NCT01708356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling on a residential route
Study NCT03520998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRF6019
Description: GRF6019 for IV infusion
Study NCT02621450 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: standart dialysis
Description: dialysate sodium consentration 140 mEq
Study NCT02621450 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: low sodium dialysis
Description: dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
Study NCT01473888 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: T89(Dantonic)
Description: capsule, 225mg B.I.D.
Study NCT05304754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells stimulated ex vivo with IL-15
Description: When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008
Study NCT05304754 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alloreactive NK cells
Description: When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
Study NCT03207295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
Study NCT03207295 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children